TREACE MEDICAL CONCEPTS, INC. (TMCI) FY2025 10-K Annual Report
TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
TREACE MEDICAL CONCEPTS, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: Development, marketing, and sales of bunion correction surgical systems and instruments in the U.S., primarily via direct sales force and distributors
- • New products emphasized: Minimally invasive osteotomy systems (Nanoplasty, Percuplasty), great toe fusion system, and next-gen Lapiplasty Lightning Instrumentation expected in 2026
- • Strategic shift: Addressing surgeon shift to minimally invasive bunion surgery with lower-priced new product lines; growing stocking distributor sales (from $0 to $13M in 2025)
- • Quantitative highlights: Active surgeons increased 6% to 3,337; direct sales force generated 80% of 2025 revenue; marketable securities $37.7M; legal expenses up $5.4M due to patent infringement lawsuits
- • Noteworthy fact: Filed multiple patent infringement lawsuits in 2024-2025 against major competitors Stryker and Zimmer Biomet over Lapiplasty 3D technology
Management Discussion & Analysis
- • Revenue $212.7M in 2025, up 1.6% YoY from $209.4M in 2024
- • Net loss increased to $59.0M in 2025 from $55.7M in 2024; operating margin negative approx. -25.5% in 2025 vs -26.6% in 2024 (loss from operations $54.2M vs $55.7M)
- • Best segment: not segmented; gross profit stable at $169.8M vs $168.3M; no segment-level details; worst metric: net loss deepening
- • Operating cash flow use $16.0M in 2025 vs $37.2M in 2024; investing cash inflow $13.3M in 2025 driven by sales/maturities of securities; financing cash inflow $2.1M in 2025 primarily from new term loan net proceeds ($59.3M) and repayments of prior loans ($56.3M)
- • Management expects existing cash, securities ($10.7M + $37.7M), and credit facilities sufficient for 12+ months; potential need to raise additional capital to support growth and operational needs; risks include market acceptance, competition, supply chain, economic factors, and litigation impacts
TREACE MEDICAL CONCEPTS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$213M
▲ +1.6% YoY
Net Income
-$59M
▼ -5.8% YoY
Gross Margin
79.8%
▼ -56bp YoY
Operating Margin
-25.5%
▲ +114bp YoY
Net Margin
-27.7%
▼ -112bp YoY
ROE
-67.6%
▼ -1818bp YoY
Total Assets
$191M
▼ -12.2% YoY
EPS (Diluted)
$-0.93
▼ -3.3% YoY
Operating Cash Flow
-$16M
▲ +57.0% YoY
Source: XBRL data from TREACE MEDICAL CONCEPTS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TREACE MEDICAL CONCEPTS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.